Beyond rodent models, a propensity score-matched cohort study of type 2 DM patients found that patients who are using SGLT2 inhibitors have a lower risk of depression compared to those using DPP4 inhibitors [352]. This evidence concerns the gene SLC5A2 and major depressive disorder.